Related Experiment Videos
Inhibitors of angiogenesis in a clinical perspective
1Department of Internal Medicine and Medical Oncology, University Hospital Utrecht, The Netherlands.
Abstract:
Inhibition of angiogenesis or preventing the outgrowth of new blood vessels towards a tumor is one of the most promising areas of anticancer drug development. Several angiogenesis inhibitors are now on the verge of being tested in clinical trials. This review discusses possible applications of inhibitors of angiogenesis and whether the current methodologies for testing novel anticancer drugs are appropriate to evaluate the efficacy of inhibitors of angiogenesis.
Insights
Angiogenesis inhibitors, crucial for anticancer drug development, aim to block tumor blood vessel growth. This review examines their applications and the suitability of current drug testing methods for evaluating their effectiveness.
Area of Science:
- Oncology
- Vascular Biology
- Drug Development
Background:
- Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis.
- Inhibiting angiogenesis is a key strategy in anticancer drug development.
- Several novel angiogenesis inhibitors are nearing clinical trials.
Purpose of the Study:
- To review the potential applications of angiogenesis inhibitors in cancer therapy.
- To assess the appropriateness of current drug testing methodologies for evaluating angiogenesis inhibitors.
Main Methods:
- Literature review of preclinical and clinical studies on angiogenesis inhibitors.
- Analysis of existing methodologies for anticancer drug efficacy testing.
- Discussion of the challenges and considerations for evaluating anti-angiogenic agents.
Main Results:
- Angiogenesis inhibitors show promise in various anticancer therapeutic strategies.
- Current drug testing models may not fully capture the efficacy of angiogenesis inhibitors.
- Specific adaptations in testing protocols are needed to accurately assess anti-angiogenic drug effects.
Conclusions:
- Angiogenesis inhibition represents a significant frontier in oncology.
- Existing drug evaluation frameworks require refinement to adequately assess novel anti-angiogenic therapies.
- Further research into optimized testing methodologies is crucial for advancing this field.